Compare Deckers Outdoor Corp (DECK) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs McKesson Corporation — how do they compare? Deckers Outdoor Corp trades at $82.9 (market cap $11.24B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 9.6× Deckers Outdoor Corp's market cap, and McKesson Corporation pays a 0.4% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and McKesson Corporation for 74 Days on average.
| DECK | MCK | |
|---|---|---|
Market Cap | $11.24B | $108.46B |
Volume | 3,010,945 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $995.69 |
52-Week Low | $77.51 | $725.17 |
Typical Hold Time | 71 Days | 74 Days |
Enterprise Value | $10.11B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers (DECK) trades at $82.89, up 3.12% recently, with a bullish technical signal and strong fundamental performance. The stock shows robust revenue growth from $3.2B in 2022 to $5.0B in 2025, with net income rising to $966M. Key brands HOKA and UGG drive momentum, supported by positive analyst sentiment and a consensus price target of $117.13. Cash flow remains healthy, though 2026 projections indicate a net cash outflow.
The outlook for DECK is positive, with earnings beats and brand strength offering upside potential. Risks include competitive pressures in footwear and reliance on key brands. Analyst consensus leans bullish, but investors should monitor execution and market volatility.
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
